Individual
DC projects
Research project
Optimization and Preclinical Evaluation of Novel SHP2 inhibitors
Rationale and Objectives
The primary objective of this project is to optimize lead compounds previously identified for targeting SHP2 mutant forms commonly found in various leukemia types, assess their physicochemical properties, and evaluate their preclinical efficacy.
The specific objectives of this research program are:
- Conducting virtual optimization of the lead SHP2 inhibitory compounds.
- Characterizing the ADME profile and toxicity of the optimized inhibitors.
- Assessing the therapeutic efficacy of the new inhibitors in leukemia models.
Estimated gross salary
40,000€/year
This project may be adapted to the evolving needs of the host laboratory while remaining within hemato-oncology research. The DC will undertake one or more secondments with a total duration of at least three months and up to one year. These secondments may take place within or outside the DN, preferably in international and intersectoral settings.